NASDAQ · Financial Statements

Harmony Biosciences Holdings, Inc. (HRMY) Revenue, Earnings & Financial Statements

$33.01 NASDAQ: HRMY Market Cap $1.94B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Harmony Biosciences Holdings, Inc. most recently reported annual revenue of $868.0M, net profit of $159.0M. Revenue grew at an average annual rate of 40.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Harmony Biosciences Holdings, Inc.: net profit was positive in 5 of 8 reported years; operating margin moved from -2433.8% to 24.0%, a shift of +2457.8 percentage points; the most recent year shows net profit of $159.0M.

Income Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Revenue$0$6.0M$160.0M$305.0M$438.0M$582.0M$715.0M$868.0M
Operating Expenses$41.0M$152.0M$143.0M$218.0M$318.0M$390.0M$524.0M$660.0M
Operating Profit−$41.0M−$146.0M$17.0M$88.0M$120.0M$192.0M$191.0M$208.0M
Operating Margin—-2433.8%10.6%28.7%27.4%33.0%26.7%24.0%
Other Income$2.0M−$6.0M−$54.0M−$50.0M−$15.0M−$19.0M$1.0M$7.0M
Interest$0$6.0M$28.0M$24.0M$19.0M$24.0M$17.0M$15.0M
Depreciation$0$3.0M$10.0M$19.0M$23.0M$24.0M$24.0M$25.0M
Profit Before Tax−$40.0M−$152.0M−$37.0M$37.0M$105.0M$173.0M$192.0M$215.0M
Tax rate (%)0.0%0.0%0.0%7.6%-73.3%25.7%24.1%26.2%
Net Profit−$40.0M−$152.0M−$37.0M$35.0M$181.0M$129.0M$145.0M$159.0M
EPS−$1.42−$2.94−$1.10$0.58$2.97$2.13$2.51$2.71

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$168.0M$155.0M$173.0M$186.0M$201.0M$185.0M$200.0M$239.0M$244.0M$215.0M$261.0M$269.0M
Operating Expenses$128.0M$103.0M$151.0M$124.0M$146.0M$128.0M$152.0M$174.0M$205.0M$178.0M$172.0M$215.0M
Operating Profit$40.0M$52.0M$21.0M$62.0M$56.0M$56.0M$48.0M$65.0M$39.0M$37.0M$89.0M$54.0M
Operating Margin23.9%33.6%12.4%33.2%27.7%30.4%24.0%27.4%15.8%17.3%34.2%20.1%
Interest$5.0M$5.0M$4.0M$4.0M$4.0M$4.0M$4.0M$4.0M$4.0M$3.0M$3.0M$3.0M
Profit Before Tax$40.0M$52.0M$22.0M$62.0M$56.0M$57.0M$50.0M$67.0M$41.0M$40.0M$93.0M$59.0M
Tax rate (%)33.0%26.0%46.6%25.9%11.9%20.3%19.9%24.6%44.8%18.1%19.1%18.7%
Net Profit$27.0M$38.0M$12.0M$46.0M$49.0M$46.0M$40.0M$51.0M$22.0M$32.0M$75.0M$48.0M
EPS$0.45$0.67$0.20$0.79$0.85$0.78$0.68$0.87$0.38$0.55$1.28$0.81

Over the 8 years reported for Harmony Biosciences Holdings, Inc., borrowings decreased from $324.0M in 2018 to $240.0M in 2025, cash stood at $753.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.60 times.

Balance Sheet — 8 Years (USD millions)

Metric20182019202020212022202320242025
Total Assets$89.0M$107.0M$427.0M$433.0M$674.0M$811.0M$999.0M$1.3B
Current Assets$87.0M$31.0M$263.0M$284.0M$400.0M$451.0M$579.0M$907.0M
Cash$84.0M$24.0M$229.0M$234.0M$244.0M$312.0M$453.0M$753.0M
Inventory$0$1.0M$4.0M$4.0M$4.0M$5.0M$7.0M$5.0M
Receivables$0$4.0M$22.0M$35.0M$55.0M$74.0M$83.0M$97.0M
Fixed Assets$2.0M$1.0M$1.0M$4.0M$1.0M$0$3.0M$5.0M
Capital Work in Progress$0$0$0$0$0$0$0$0
Investments$1.0M$0$0$0$102.0M$114.0M$123.0M$130.0M
Other Assets$0$0$0$0$0$0$0$0
Total Liabilities$8.0M$118.0M$330.0M$247.0M$271.0M$344.0M$340.0M$401.0M
Current Liabilities$7.0M$20.0M$135.0M$54.0M$79.0M$164.0M$175.0M$252.0M
Borrowings$324.0M$98.0M$194.0M$196.0M$192.0M$194.0M$181.0M$240.0M
Other Liabilities$0$20.0M$136.0M$51.0M$79.0M$151.0M$159.0M$162.0M
Equity$0$0$0$0$0$0$0$0
Reserves$82.0M−$12.0M$97.0M$187.0M$403.0M$467.0M$659.0M$870.0M

For Harmony Biosciences Holdings, Inc., operating cash flow was positive in 5 of 8 reported years; free cash flow in the latest year was $348.0M; free cash flow was positive in 5 of 8 years; financing activities used $3.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Operating Cash Flow−$39.0M−$75.0M−$3.0M$99.0M$144.0M$219.0M$220.0M$348.0M
Investing Cash Flow−$3.0M−$127.0M−$4.0M−$101.0M−$142.0M−$47.0M−$69.0M−$40.0M
Financing Cash Flow−$3.0M$44.0M$130.0M$8.0M$9.0M−$104.0M−$2.0M−$3.0M
Net Cash Flow−$19.0M−$59.0M$204.0M$6.0M$9.0M$67.0M$141.0M$300.0M
Free Cash Flow−$40.0M−$76.0M−$5.0M$98.0M$144.0M$219.0M$219.0M$348.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2.22
EV / EBITDA5.48
FCF Yield16.27%
Quick Ratio3.42
Interest Coverage16.98
Return 1Y-1.55%
Return 3Y34.56%
Return 5Y-19.54%

Harmony Biosciences Holdings, Inc. (HRMY) financials — frequently asked questions

What is Harmony Biosciences Holdings, Inc.'s annual revenue?

Harmony Biosciences Holdings, Inc. (HRMY) reported annual revenue of $868.0M in its most recent fiscal year.

What is Harmony Biosciences Holdings, Inc.'s net profit?

Harmony Biosciences Holdings, Inc. (HRMY) reported net profit of $159.0M in its most recent fiscal year.

What is HRMY EV/EBITDA?

Harmony Biosciences Holdings, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 5.48.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
HRMY Overview HRMY Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.